SHSharon L. Hillier

Sharon L. Hillier

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sharon L. Hillier has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Alicia Liu

    Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine , Pittsburgh, Pennsylvania

    1 shared publication
  • Anne-Marie Rick

    Department of Pediatrics, University of Pittsburgh School of Medicine , Pittsburgh, Pennsylvania

    1 shared publication
  • Caitlin Little

    Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine , Pittsburgh, Pennsylvania

    1 shared publication
  • Christina Megli

    Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine , Pittsburgh, Pennsylvania

    1 shared publication
  • Elizabeth R Brown

    Fred Hutchinson Cancer Center , Seattle, Washington

    1 shared publication
  • Felix Mhlanga

    University of Zimbabwe College of Health Sciences Clinical Trials Research Centre , Harare

    1 shared publication

Latest Publications

  • Open Access

    Comparing BD Affirm VPIII to Xpert Xpress MVP and BD MAX Vaginal Panel for the diagnosis of vaginal infections

    by Lisa A. Cosentino, Melinda Petrina, Tracy Zamborsky, May Beamer, Ingrid Macio, Leslie A. Meyn, Katherine E. Bunge, Sharon L. Hillier

    BD Affirm VPIII, a non-amplified molecular test for the detection of Candida, Trichomonas vaginalis (TV), and Gardnerella vaginalis (GV), was compared to two nucleic acid amplification tests (NAATs), the Xpert Xpress MVP and BD MAX Vaginal Panel, to estimate its sensitivity and specificity for the diagnosis of vaginitis/vaginosis. Women ≥14 years old, seeking care with symptoms of vaginitis (vaginal discharge, odor, vulvar or vaginal itch, irritation, and burning), provided self-collected vaginal samples for the Xpert Swab Specimen Collection (Xpert Xpress MVP), BD Molecular Swab Collection (BD MAX Vaginal Panel), and BD Affirm Ambient Temperature Transport System (BD Affirm VPIII). True positive and negative results were defined as concordant results on both NAATs. Agreement between the NAATs was 96% for bacterial vaginosis (BV), 95% for Candida, and 100% for TV. Based on both NAATs, the prevalence of BV in the population was estimated to be 42.8% (118/276), 28.3% (78/276) for Candida, and 5.1% (14/276) for TV. The BD Affirm VPIII detected only 43% of TV and 56% of Candida. While the sensitivity of GV for BV was 89.7% (95% confidence interval [CI]: 82.6–94.5), the specificity was 76.2% (95% CI: 68.4–82.9). Of women with no BV, Candida , or TV by NAAT, 29.5% would have been misdiagnosed based on Affirm VPIII. Reliance on GV for the diagnosis of BV results in false positives in women without BV and could trigger unwarranted treatment. The inadequate sensitivity of Affirm VPIII for Candida and TV and poor specificity for BV limits its utility in clinical settings for women with symptomatic vaginitis. IMPORTANCE: Vaginal infections are common among women of reproductive age, with substantial costs for women and health systems. Point-of-care methods widely used in clinical practice to diagnose bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis include microscopy, pH testing, and amine odor. Microscopy for motile trichomonads or the pseudohyphae of Candida is insensitive because Candida or Trichomonas vaginalis can cause symptoms even when present in concentrations not detectable by direct microscopy. When microscopy is not available, the U.S. Centers for Disease Control and Prevention has recommended the use of other tests, including nonamplified DNA probe technology. Our study compared this system to two FDA-cleared amplified testing systems for the diagnosis of vaginitis. The nonamplified system was insensitive for the detection of Candida and Trichomonas vaginalis and nonspecific for bacterial vaginosis, which could result in inappropriate treatment and misdiagnosis, limiting its clinical utility for use in women with vaginitis symptoms.


  • Open Access

    Vaginal Microbiota and Cytokines Among Pregnant and Breastfeeding Women in Clinical Trials of the Dapivirine Vaginal Ring and Oral Tenofovir Disoproxil Fumarate/Emtricitabine

    by Melinda A B Petrina, Tracy Q Dong, May Beamer, Katherine Bunge, Lee Fairlie, Felix Mhlanga, Jennifer E Balkus, Lisa M Noguchi, Jeanna Piper, Elizabeth R Brown, et al.

    Background: Vaginal dysbiosis is associated with HIV acquisition and preterm delivery. Our objective was to evaluate prevalent vaginal infections, and changes in microbiota and cytokines among pregnant and breastfeeding women from 4 African countries using dapivirine vaginal ring (DVR) or oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in 2 parallel nonoverlapping trials. Methods: MTN-042 (NCT03965923) was a randomized trial evaluating daily TDF/FTC or monthly DVR during pregnancy (n = 558), and MTN-043 (NCT04140266) was a randomized study evaluating TDF/FTC or DVR during breastfeeding (n = 197). Women were evaluated for vaginal infections at enrollment and follow-up using Nugent score and BD Max™ Vaginal Panel. Microbiota was evaluated by quantitative PCR for 12 bacterial targets; 5 cytokines and RANTES were evaluated by MAGPIX. Rates of change in vaginal microbiota and cytokines and prevalence of vaginal infections were evaluated using generalized linear mixed models and Benjamini–Hochberg (BH)-adjusted P values. Results: Vaginal infections, microbiota and cytokines did not differ between the 2 study arms at baseline. Lactobacillus crispatus was less frequently detected postpartum and during breastfeeding compared with pregnancy. Bacterial vaginosis (BV) and Candida were common during pregnancy and breastfeeding, but there was no significant difference in the rate of change in these infections by study arm. BV-associated microbiota and cytokines changed over pregnancy and postpartum, but the rate of change by study arm did not differ. Conclusions: Vaginal infections, microbiota or cytokines/chemokines changes were similar in women using DVR or TDF/FTC. These data augment the robust safety profile for DVR to support its use during pregnancy and breastfeeding.

  • Open Access

    Placental Pathogens Associated With Adverse Maternal and Neonatal Outcomes

    by Alicia Liu, Caitlin Little, Talia Dubowitz, Malinda Schaeffer, Lauren Skvarca, Anne-Marie Rick, Thomas Hooven, Michael Morowitz, Sharon L Hillier, Harold C Wiesenfeld, et al.

    Background: Bacterial infection at the maternal-fetal interface contributes to adverse pregnancy outcomes, including preterm birth, chorioamnionitis, and sepsis. Despite evolving obstetric practices that may influence microbial patterns, recommended clinical algorithms for prophylaxis and treatment rely on outdated data. Furthermore, the pathogenic organisms associated with adverse outcomes remain incompletely characterized. Methods: We conducted a retrospective study of placental cultures from a high-risk obstetric cohort from a single hospital system between 2014 and 2019 (n = 714). Placental cultures were obtained from deliveries at high risk for infection: (eg, preterm birth or suspected chorioamnionitis). Placental cultures were stratified into pathogenic and nonpathogenic. Associated clinical outcomes, histopathology, and antimicrobial susceptibility patterns were compared. Results: Pathogenic organisms were identified in 69% of cultures (492 of 714). Group B Streptococcus (n = 161; 22.5% of total isolates) and Escherichia coli (n = 53; 7.4% of total isolates) were the most common pathogens isolated; we also identified additional pathogens, including Enterococcus faecalis (n = 44), Haemophilus (n = 37), Prevotella (n = 32), and Bacteroides species (n = 23). Pathogenic cultures were correlated with significantly higher rates of composite adverse maternal (27.0% vs 17.6%; P = .006) and neonatal (78.9% vs 60.6%; P < .001) outcomes, as well as histopathologic chorioamnionitis (72.5% vs 60.9%; P = .003). Antimicrobial resistance for recommended empiric regimens ranged from 47.1% to 87.8%. Conclusions: Bacterial pathogens isolated from the placenta in high-risk pregnancies are associated with perinatal morbidity. Group B Streptococcus and E coli remain common, and E faecalis, Haemophilus spp, and anaerobes such as Prevotella may represent emerging pathogens underrecognized in contemporary obstetric practice. Placental cultures may serve as a valuable surveillance tool for informing empiric antibiotic strategies in pregnancy.